Trigemina Inc.’s founders and scientists include some of the world’s foremost researchers in the field of analgesic delivery through nasal-cerebral pathways. We are focused on developing new, non-opioid, non-sedating, cognition-neutral drug formulations and delivery systems with the promise of pain relief that is as safe as it is strong, a combination which has largely eluded doctors, pharmaceutical companies and, most importantly, patients who suffer from debilitating or chronic pain.
We are currently testing our lead product candidate, TI – 001, in Phase 2 clinical trials for patients suffering from chronic migraine and high frequency episodic migraine. This therapy may also hold promise for treating other chronic head pain, such as temporomandibular joint disorder (TMJ), traumatic brain injury and post-maxillofacial surgery pain.
Trigemina was founded in 2006 by a team of doctors and researchers led by Dr. David Yeomans, the director of pain research at Stanford University School of Medicine.